Archive

ASCO Daily News Archive

The ASCO Daily News is the official news source for the ASCO-SITC Clinical Immuno-Oncology Symposium, providing expert perspectives on controversial topics and session highlights. Articles include physician-authored “Expert Editorials” on current clinical issues in oncology, interviews with Meeting attendees, and recaps of key sessions and presentations. Content is current as of the Meeting date and may not reflect the most recent data.


March 13, 2017

The 2017 Clinical Immuno-Oncology Symposium achieves a successful first year, with 950 researchers and clinicians gathering to learn about state-of-the-art developments in the science and application of immuno-oncology and further drive the field forward.

Read more

February 26, 2017

Analysis of patients with neuroblastoma receiving anti-GD2 therapy reveals that polymorphisms in receptors on NK cells influences ADCC activity and correlates with patient survival.

Read more

February 25, 2017

Combining PD-1 and CTLA-4 inhibition in squamous cell carcinoma of the head and neck may help to boost treatment responses, according to exploratory analyses of circulating immune cells obtained from CheckMate 141 participants.

Read more

February 25, 2017

Dr. Limo Chen and colleagues have identified CD38 as a novel immune checkpoint protein—one that works by inhibiting CD8+ T-cell function and that overcomes resistance to inhibition of the PD-1/PD-L1 axis in lung cancer models.

Read more

February 24, 2017

In-depth molecular analyses of T cells within the microenvironment suggest that metastatic melanoma is not a singular disease within an individual patient but, rather, a collection of different lesions potentially subject to different local immune composition, regulation, and recognition.

Read more

February 24, 2017

Research in patients with metastatic melanoma identifies links between the diversity and composition of the bacteria comprising the gut and the response to anti–PD-1 therapy.

Read more

February 24, 2017

Immune biomarkers offer insight into past and ongoing interactions between the immune system and cancer—key intelligence that researchers can exploit to more appropriately apply select immunotherapies.

Read more

February 24, 2017

A prospective phase II trial shows that adding plinabulin to docetaxel in patients with previously treated advanced NSCLC dramatically boosts the duration of response, extends OS, and protects against neutropenia, paving the way for a larger phase III study.

Read more

February 23, 2017

Modeling analyses estimate that 21% to 25% of patients with PD-L1–positive advanced NSCLC who previously received platinum-containing chemotherapy will survive more than 5 years following treatment pembrolizumab, as compared with only 3% to 4% of patients treated with docetaxel.

Read more

February 23, 2017

In instances where cancers manage to evade the immune system and grow, emerging strategies are showing promise for training or retraining the immune system to recognize tumor-specific antigens and attack the tumors bearing them.

Read more
February 23, 2017

The ASCO Daily News podcast is dedicated to providing ASCO members and meeting attendees more of the high-quality information they’ve come to expect from the ASCO Daily News. 

Read more

February 17, 2017

ASCO and NCCN announce a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy.

Read more

February 16, 2017

Dr. Catherine Lai discusses why she is excited to attend the inaugural ASCO-SITC Clinical Immuno-Oncology Symposium.

Read more

February 16, 2017

Dr. Marie-Andrée Forget discusses why she is attending the inaugural ASCO-SITC Clinical Immuno-Oncology Symposium.

Read more

February 16, 2017

These sessions will give attendees the tools to not only discuss immunotherapy with their patients, but incorporate practical applications of immunology research into their clinical practice.

Read more

February 16, 2017

Dr. Ronald Germain will discuss the use of advanced microscopy methods in assessment of anticancer immune responses.

Read more

February 16, 2017

Prof. Laurence Zitvogel will discuss the association between the gut microbiota and therapeutic effectiveness of alkylating agents, platinum salts, and immune checkpoint inhibitors.

Read more

February 16, 2017

Dr. Robert Schreiber will discuss cancer immunoediting and provide an overview of published and unpublished findings demonstrating that neoantigens are the favored targets of T cells during immunotherapy-induced responses to established tumors.

Read more

February 16, 2017

Dr. Gilberto Lopes named editor-in-chief of the Journal of Global Oncology.

Read more

February 16, 2017

What are the immunotherapy options for patients with melanoma and active autoimmune disease?

Read more